Tipiracil (hydrochloride)

Tipiracil (hydrochloride)

• CAS Number: 183204-72-0
• UNSPSC Description: Tipiracil (hydrochloride) is a thymidine phosphorylase inhibitor (TPI), used for cancer research.
• Target Antigen: Nucleoside Antimetabolite/Analog
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Tipiracil-hydrochloride.html
• Purity: 99.93
• Solubility: DMF : < 1 mg/mL|DMSO : < 1 mg/mL|H2O : 50 mg/mL (ultrasonic)
• Smiles: [H]Cl.O=C1C(Cl)=C(CN2C(CCC2)=N)NC(N1)=O
• Molecular Weight: 279.12
• References & Citations: [1]Peters GJ, et al. TAS-102: more than an antimetabolite. Lancet Oncol. 2012 Dec;13(12):e518-9.|[2]Yoshino T, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012 Oct;13(10):993-1001.Biomed Pharmacother. 2021 May 6;139:111672.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Mod Rheumatol. 2018 May;28(3):495-505.|Patent. US Patent 11110111.|Oncol Rep. 2023 Mar;49(3):52.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched